【产品介绍】：

生物活性：Teneligliptin-d8 is a deuterium labeled Teneligliptin (MP-513). Teneligliptin is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor[1].
IC50 & Target：DPP-4
Clinical Trial
NCT NumberSponsorConditionStart DatePhaseNCT02449330National Cerebral and Cardiovascular CenterDiabetes Mellitus, Type 2June 2015Phase 4NCT02924064Mitsubishi Tanabe Pharma CorporationType 2 Diabetes MellitusSeptember 2016Phase 3NCT02567994Handok Inc.Type 2 Diabetes MellitusApril 2015Phase 3 NCT00628212Mitsubishi Tanabe Pharma CorporationType 2 DiabetesJanuary 2008Phase 2NCT03769870Handok Inc.Diabete MellitusJanuary 11, 2019Phase 1NCT05504239Handok Inc.Type 2 DiabetesOctober 2022Phase 3NCT03793023Handok Inc.Type 2 Diabetes MellitusJanuary 2016NCT04431141Handok Inc.Type 2 Diabetes MellitusSeptember 15, 2020Phase 1NCT02512523Handok Inc.Type 2 Diabetes MellitusAugust 2015Phase 4NCT02314637Mitsubishi Tanabe Pharma CorporationType 2 Diabetes MellitusAugust 2009Phase 3NCT02354222Mitsubishi Tanabe Pharma CorporationType 2 Diabetes MellitusJanuary 2015Phase 3NCT02354235Mitsubishi Tanabe Pharma CorporationType 2 Diabetes MellitusJanuary 2015Phase 3NCT01798238Handok Inc.Type 2 Diabetes MellitusNovember 2012Phase 3NCT00971243Mitsubishi Tanabe Pharma CorporationType 2 Diabetes MellitusAugust 2009Phase 2NCT04446026Yonsei UniversityType 2 Diabetes MellitusJuly 8, 2020Phase 4NCT03011177Handok Inc.Type2 Diabetes MellitusJanuary 2017Phase 4NCT01805830Handok Inc.Type 2 DiabetesMay 2012Phase 3NCT00974090Mitsubishi Tanabe Pharma CorporationType 2 Diabetes MellitusSeptember 2009Phase 3NCT02916706Mitsubishi Tanabe Pharma CorporationType 2 Diabetes MellitusSeptember 2016Phase 3NCT02081599Mitsubishi Tanabe Pharma CorporationType 2 Diabetes MellitusJanuary 2014Phase 4NCT01072331Mitsubishi Tanabe Pharma CorporationType 2 Diabetes MellitusFebruary 2010Phase 3NCT05504226Handok Inc.Type 2 DiabetesOctober 2022Phase 3NCT03787017Handok Inc.Healthy VolunteersJanuary 2014Phase 1NCT00998881Mitsubishi Tanabe Pharma CorporationType 2 Diabetes MellitusSeptember 2009Phase 3NCT03508323Handok Inc.Type 2 Diabetes MellitusApril 3, 2018Phase 4NCT01026194Mitsubishi Tanabe Pharma CorporationType 2 Diabetes MellitusDecember 2009Phase 3NCT01301833Mitsubishi Tanabe Pharma CorporationType 2 Diabetes MellitusFebruary 2011Phase 3
分子量：434.63
Formula：C22H22D8N6OS
CAS 号：1391012-95-5
非标记 CAS：760937-92-6
中文名称：替格列汀 d8
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (525 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Fukuda-Tsuru S, et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol. 2012 Dec 5;696(1-3):194-202.
 [Content Brief]